Phase 2
Completed N=40
Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis
Trichomonas Vaginitis
Source: ClinicalTrials.gov NCT01361048 ↗
Enrolled (actual)
40
Serious AEs
2.5%
Results posted
Feb 2014
Primary outcomePrimary: Percentage of Participants Cured of Vaginal Trichmonas — 90; 90; 88 percentage of participants
Summary
The investigators are trying a combination vaginal product of higher dose metronidazole combined with miconazole to see if it is effective in treating vaginal trichomonas.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Cured of Vaginal Trichmonas |
90; 90; 88 | — |
| SECONDARY Tolerability of the Study Product as Measured by Participant Self-report |
2; 1; 0 | — |
Eligibility Criteria
Inclusion Criteria
- presence of trichomonas
Exclusion Criteria
- pregnant or nursing
- known immunodeficiency
- allergy to study drugs
- concurrent yeast infection
- history of seizures or peripheral neuropathy
- unwillingness to abstain from alcohol during treatment period and for 48 hrs after concurrent lithium
- anticoagulation therapy, and abuse
- patient expected to have menses within 8 days of enrollment
Data sourced from ClinicalTrials.gov (NCT01361048). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.